Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates

Gilbert J. L'Italien, Sumita D. Paul, Robert Hendel, Jeffrey A. Leppo, Mylan C. Cohen, Lee A. Fleisher, Kenneth A. Brown, Stuart W. Zarich, Richard P. Cambria, Bruce S. Cutler, Kim A. Eagle

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Objectives. This study sought to develop and validate a Bayesian risk prediction model for vascular surgery candidates. Background. Patients who require surgical treatment of peripheral vascular disease are at increased risk of perioperative cardiac morbidity and mortality. Existing prediction models tend to underestimate risk in vascular surgery candidates. Methods. The cohort comprised 1,081 consecutive vascular surgery candidates at five medical centers. Of these, 567 patients from two centers ('training' set) were used to develop the model, and 514 patients from three centers were used to validate it ('validation' set). Risk scores were developed using logistic regression for clinical variables: advanced age (>70 years), angina, history of myocardial infarction, diabetes mellitus, history of congestive heart failure and prior coronary revascularization. A second model was developed from dipyridamole-thallium predictors of myocardial infarction (i.e., fixed and reversible myocardial defects and ST changes). Model performance was assessed by comparing observed event rates with risk estimates and by perform ing receiver-operating characteristic curve (ROC) analysis. Results. The postoperative cardiac event rate was 8% for both sets. Prognostic accuracy (i.e., ROC area) was 74 ± 3% (mean ± SD) for the clinical and 81 ± 3% for the clinical and dipyridamole-thallium models. Among the validation sets, areas were 74 ± 9%, 72 ± 7% and 76 ± 5% for each center. Observed and estimated rates were comparable for both sets. By the clinical model, the observed rates were 3%, 8% and 18% for patients classified as low, moderate and high risk by clinical factors (p < 0.0001). The addition of dipyridamole-thallium data reclassified >80% of the moderate risk patients into low (3%) and high (19%) risk categories (p < 0.0001) but provided no stratification for patients classified as low or high risk according to the clinical model. Conclusions. Simple clinical markers, weighted according to prognostic impact, will reliably; stratify risk in vascular surgery candidates referred for dipyridamole-thallium testing, thus obviating the need for the more expensive testing. Our prediction model retains its prognostic accuracy when applied to the validation sets and can reliably estimate risk in this group.

Original languageEnglish
Pages (from-to)779-786
Number of pages8
JournalJournal of the American College of Cardiology
Volume27
Issue number4
DOIs
StatePublished - Mar 15 1996
Externally publishedYes

Fingerprint

Blood Vessels
Dipyridamole
Thallium
ROC Curve
Myocardial Infarction
Bayes Theorem
Peripheral Vascular Diseases
Diabetes Mellitus
Heart Failure
Biomarkers
Logistic Models
Morbidity
Mortality

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. / L'Italien, Gilbert J.; Paul, Sumita D.; Hendel, Robert; Leppo, Jeffrey A.; Cohen, Mylan C.; Fleisher, Lee A.; Brown, Kenneth A.; Zarich, Stuart W.; Cambria, Richard P.; Cutler, Bruce S.; Eagle, Kim A.

In: Journal of the American College of Cardiology, Vol. 27, No. 4, 15.03.1996, p. 779-786.

Research output: Contribution to journalArticle

L'Italien, GJ, Paul, SD, Hendel, R, Leppo, JA, Cohen, MC, Fleisher, LA, Brown, KA, Zarich, SW, Cambria, RP, Cutler, BS & Eagle, KA 1996, 'Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates', Journal of the American College of Cardiology, vol. 27, no. 4, pp. 779-786. https://doi.org/10.1016/0735-1097(95)00566-8
L'Italien, Gilbert J. ; Paul, Sumita D. ; Hendel, Robert ; Leppo, Jeffrey A. ; Cohen, Mylan C. ; Fleisher, Lee A. ; Brown, Kenneth A. ; Zarich, Stuart W. ; Cambria, Richard P. ; Cutler, Bruce S. ; Eagle, Kim A. / Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. In: Journal of the American College of Cardiology. 1996 ; Vol. 27, No. 4. pp. 779-786.
@article{77bdb3b4200e4f33869001dc955d7bdd,
title = "Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates",
abstract = "Objectives. This study sought to develop and validate a Bayesian risk prediction model for vascular surgery candidates. Background. Patients who require surgical treatment of peripheral vascular disease are at increased risk of perioperative cardiac morbidity and mortality. Existing prediction models tend to underestimate risk in vascular surgery candidates. Methods. The cohort comprised 1,081 consecutive vascular surgery candidates at five medical centers. Of these, 567 patients from two centers ('training' set) were used to develop the model, and 514 patients from three centers were used to validate it ('validation' set). Risk scores were developed using logistic regression for clinical variables: advanced age (>70 years), angina, history of myocardial infarction, diabetes mellitus, history of congestive heart failure and prior coronary revascularization. A second model was developed from dipyridamole-thallium predictors of myocardial infarction (i.e., fixed and reversible myocardial defects and ST changes). Model performance was assessed by comparing observed event rates with risk estimates and by perform ing receiver-operating characteristic curve (ROC) analysis. Results. The postoperative cardiac event rate was 8{\%} for both sets. Prognostic accuracy (i.e., ROC area) was 74 ± 3{\%} (mean ± SD) for the clinical and 81 ± 3{\%} for the clinical and dipyridamole-thallium models. Among the validation sets, areas were 74 ± 9{\%}, 72 ± 7{\%} and 76 ± 5{\%} for each center. Observed and estimated rates were comparable for both sets. By the clinical model, the observed rates were 3{\%}, 8{\%} and 18{\%} for patients classified as low, moderate and high risk by clinical factors (p < 0.0001). The addition of dipyridamole-thallium data reclassified >80{\%} of the moderate risk patients into low (3{\%}) and high (19{\%}) risk categories (p < 0.0001) but provided no stratification for patients classified as low or high risk according to the clinical model. Conclusions. Simple clinical markers, weighted according to prognostic impact, will reliably; stratify risk in vascular surgery candidates referred for dipyridamole-thallium testing, thus obviating the need for the more expensive testing. Our prediction model retains its prognostic accuracy when applied to the validation sets and can reliably estimate risk in this group.",
author = "L'Italien, {Gilbert J.} and Paul, {Sumita D.} and Robert Hendel and Leppo, {Jeffrey A.} and Cohen, {Mylan C.} and Fleisher, {Lee A.} and Brown, {Kenneth A.} and Zarich, {Stuart W.} and Cambria, {Richard P.} and Cutler, {Bruce S.} and Eagle, {Kim A.}",
year = "1996",
month = "3",
day = "15",
doi = "10.1016/0735-1097(95)00566-8",
language = "English",
volume = "27",
pages = "779--786",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates

AU - L'Italien, Gilbert J.

AU - Paul, Sumita D.

AU - Hendel, Robert

AU - Leppo, Jeffrey A.

AU - Cohen, Mylan C.

AU - Fleisher, Lee A.

AU - Brown, Kenneth A.

AU - Zarich, Stuart W.

AU - Cambria, Richard P.

AU - Cutler, Bruce S.

AU - Eagle, Kim A.

PY - 1996/3/15

Y1 - 1996/3/15

N2 - Objectives. This study sought to develop and validate a Bayesian risk prediction model for vascular surgery candidates. Background. Patients who require surgical treatment of peripheral vascular disease are at increased risk of perioperative cardiac morbidity and mortality. Existing prediction models tend to underestimate risk in vascular surgery candidates. Methods. The cohort comprised 1,081 consecutive vascular surgery candidates at five medical centers. Of these, 567 patients from two centers ('training' set) were used to develop the model, and 514 patients from three centers were used to validate it ('validation' set). Risk scores were developed using logistic regression for clinical variables: advanced age (>70 years), angina, history of myocardial infarction, diabetes mellitus, history of congestive heart failure and prior coronary revascularization. A second model was developed from dipyridamole-thallium predictors of myocardial infarction (i.e., fixed and reversible myocardial defects and ST changes). Model performance was assessed by comparing observed event rates with risk estimates and by perform ing receiver-operating characteristic curve (ROC) analysis. Results. The postoperative cardiac event rate was 8% for both sets. Prognostic accuracy (i.e., ROC area) was 74 ± 3% (mean ± SD) for the clinical and 81 ± 3% for the clinical and dipyridamole-thallium models. Among the validation sets, areas were 74 ± 9%, 72 ± 7% and 76 ± 5% for each center. Observed and estimated rates were comparable for both sets. By the clinical model, the observed rates were 3%, 8% and 18% for patients classified as low, moderate and high risk by clinical factors (p < 0.0001). The addition of dipyridamole-thallium data reclassified >80% of the moderate risk patients into low (3%) and high (19%) risk categories (p < 0.0001) but provided no stratification for patients classified as low or high risk according to the clinical model. Conclusions. Simple clinical markers, weighted according to prognostic impact, will reliably; stratify risk in vascular surgery candidates referred for dipyridamole-thallium testing, thus obviating the need for the more expensive testing. Our prediction model retains its prognostic accuracy when applied to the validation sets and can reliably estimate risk in this group.

AB - Objectives. This study sought to develop and validate a Bayesian risk prediction model for vascular surgery candidates. Background. Patients who require surgical treatment of peripheral vascular disease are at increased risk of perioperative cardiac morbidity and mortality. Existing prediction models tend to underestimate risk in vascular surgery candidates. Methods. The cohort comprised 1,081 consecutive vascular surgery candidates at five medical centers. Of these, 567 patients from two centers ('training' set) were used to develop the model, and 514 patients from three centers were used to validate it ('validation' set). Risk scores were developed using logistic regression for clinical variables: advanced age (>70 years), angina, history of myocardial infarction, diabetes mellitus, history of congestive heart failure and prior coronary revascularization. A second model was developed from dipyridamole-thallium predictors of myocardial infarction (i.e., fixed and reversible myocardial defects and ST changes). Model performance was assessed by comparing observed event rates with risk estimates and by perform ing receiver-operating characteristic curve (ROC) analysis. Results. The postoperative cardiac event rate was 8% for both sets. Prognostic accuracy (i.e., ROC area) was 74 ± 3% (mean ± SD) for the clinical and 81 ± 3% for the clinical and dipyridamole-thallium models. Among the validation sets, areas were 74 ± 9%, 72 ± 7% and 76 ± 5% for each center. Observed and estimated rates were comparable for both sets. By the clinical model, the observed rates were 3%, 8% and 18% for patients classified as low, moderate and high risk by clinical factors (p < 0.0001). The addition of dipyridamole-thallium data reclassified >80% of the moderate risk patients into low (3%) and high (19%) risk categories (p < 0.0001) but provided no stratification for patients classified as low or high risk according to the clinical model. Conclusions. Simple clinical markers, weighted according to prognostic impact, will reliably; stratify risk in vascular surgery candidates referred for dipyridamole-thallium testing, thus obviating the need for the more expensive testing. Our prediction model retains its prognostic accuracy when applied to the validation sets and can reliably estimate risk in this group.

UR - http://www.scopus.com/inward/record.url?scp=0030003516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030003516&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(95)00566-8

DO - 10.1016/0735-1097(95)00566-8

M3 - Article

C2 - 8613603

AN - SCOPUS:0030003516

VL - 27

SP - 779

EP - 786

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 4

ER -